NCT00722566

A Study of Subcutaneous and Intravenous VELCADE in Patients With Previously Treated Multiple Myeloma

An Open-Label Randomized Study of Subcutaneous and Intravenous VELCADE in Subjects With Previously Treated Multiple Myeloma

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 222 (actual)
• Sponsor: Millennium Pharmaceuticals, Inc. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Randomized, open-label, international, multi-center, Phase 3 study in which patients are randomized to receive VELCADE administered by subcutaneous injection or intravenous infusion.

Conditions

• Multiple Myeloma

Interventions

Type	Name	Description
DRUG	VELCADE Administered by subcutaneous injection	Patients will receive a 1.3mg/meters(squared)/dose of VELCADE on Days 1,4,8, and 11 of a 3-week cycle
DRUG	VELCADE Administered by intravenous infusion	Patients will receive a 1.3mg/meters(squared) dose of VELCADE on Days 1,4,8, and 11 of a 3-week cycle.

Timeline

• Start date: 2008-07-01
• Primary completion: 2010-08-01
• Completion: 2010-09-01
• First posted: 2008-07-25
• Last updated: 2011-10-10
• Results posted: 2011-10-04

Locations

3 sites across 3 countries: Belgium, France, Germany